AU
UK
CA
NZ
IND
US
Moleculin Biotech, Inc. (NASDAQ: MBRX)is a Houston-based clinical-stage pharmaceutical company focused on the development of oncology therapeutics. Its lead candidates include Annamycin (in development for AML and other cancers), WP1066 (targeting glioblastoma and brain metastases), and other molecules designed to exploit tumor-specific pathways. The …
Axsome Therapeutics Inc. (NASDAQ: AXSM) experienced a slight drop in its share price this week, following a downgrade by Royal Bank of Canada. The firm adjusted its rating fromOutperformtoMarket Perform, citing a reassessment of valuation metrics and future growth assumptions.
Genflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF), a UK-based biotechnology company with research operations in Belgium, has provided a mid-year update on its gene therapy pipeline focused on aging and age-related diseases. The company, which holds exclusive rights to SIRT6 gene variants associated with longevity, has reported …
Amazfit, the wearable technology brand owned by Zepp Health (NYSE: ZEPP), has launched a new square version of its recently introduced Active 2 smartwatch. Revealed at CES 2025 and also featured at Pepcom and ShowStoppers, the Amazfit Active 2 Square is designed for consumers …
Shares ofXenon Pharmaceuticals Inc. (NASDAQ:XENE)declined by 3.4% during mid-day trading on Monday, reaching an intraday low ofUSD31.57before slightly recovering to close atUSD31.64. The trading volume stood at82,081 shares, sharply lower than the company’s average daily volume of558,820 shares, reflecting an 85% drop.
Bausch Health Companies Inc. (NYSE:BHC) saw its stock price decline by 2.9% during mid-day trading on Monday, reaching a low of USD 5.72 before closing slightly higher at USD 5.81. The session’s trading volume was significantly below average, with 705,733 shares exchanged — a …
Prothena Corporation plc (NASDAQ:PRTA)is a clinical-stage biotechnology company focused on developing therapies targeting protein dysregulation in neurodegenerative and rare peripheral amyloid diseases. Its pipeline includes investigational therapies for conditions such as ATTR amyloidosis, Alzheimer’s disease, Parkinson’s disease, and other disorders involving misfolded proteins. The …
BioArctic AB (publ) (Nasdaq Stockholm: BIOA B)based in Sweden, focuses on research and development of therapies aimed at neurodegenerative diseases. The company previously partnered with Eisai on the development of Leqembi® (lecanemab), an approved treatment for early Alzheimer’s disease. Beyond Alzheimer’s, BioArctic is pursuing …
Moderna, Inc. (NASDAQ: MRNA)based in Cambridge, Massachusetts, develops mRNA-based vaccines and therapeutics for infectious diseases, cancer, rare conditions, and autoimmune disorders.
BeOne Medicines Ltd. (NASDAQ:ONC)has announced that the U.S. Food and Drug Administration (FDA) has approved a tablet version of its BTK inhibitor BRUKINSA® (zanubrutinib). The tablet formulation is approved for use across all five existing indications in the United States.
Please wait processing your request...